Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 107

1.

Statins--increasing or reducing the risk of Parkinson's disease?

Dolga AM, Culmsee C, de Lau L, Winter Y, Oertel WH, Luiten PG, Eisel UL.

Exp Neurol. 2011 Mar;228(1):1-4. doi: 10.1016/j.expneurol.2010.11.013. Epub 2010 Nov 24. Review. No abstract available.

PMID:
21111736
2.

Cholesterol levels, statins, and Parkinson's disease.

Rizvi Z, Hilas O.

Consult Pharm. 2008 May;23(5):408, 411. No abstract available.

PMID:
18540794
3.

Role of HMG-CoA reductase inhibitors in neurological disorders : progress to date.

Reiss AB, Wirkowski E.

Drugs. 2007;67(15):2111-20. Review.

PMID:
17927279
4.

Glutamic acid decarboxylase mRNA expression in medial and lateral pallidal neurons in the MPTP-treated monkey and patients with Parkinson's disease.

Herrero MT, Levy R, Ruberg M, Javoy-Agid F, Luquin MR, Agid Y, Hirsch EC, Obeso JA.

Adv Neurol. 1996;69:209-16. No abstract available.

PMID:
8615130
5.

Toxins, genetics, and Parkinson's disease: the role of N-acetyltransferase 2.

Bandmann O, Vaughan J, Holmans PA, Marsden CD, Wood NW.

Adv Neurol. 1999;80:199-204. No abstract available.

PMID:
10410722
6.

Holding on to statins in Parkinson disease.

Tan EK, Tan LC.

Neurology. 2013 Jul 30;81(5):406-7. doi: 10.1212/WNL.0b013e31829d87bb. Epub 2013 Jul 24. No abstract available.

PMID:
23884043
7.

The 3-hydroxy-3-methylglutaryl-CoA reductase inhibitor lovastatin reduces severity of L-DOPA-induced abnormal involuntary movements in experimental Parkinson's disease.

Schuster S, Nadjar A, Guo JT, Li Q, Ittrich C, Hengerer B, Bezard E.

J Neurosci. 2008 Apr 23;28(17):4311-6. doi: 10.1523/JNEUROSCI.4720-07.2008.

8.

Statin use and the risk of Parkinson disease.

Wahner AD, Bronstein JM, Bordelon YM, Ritz B.

Neurology. 2008 Apr 15;70(16 Pt 2):1418-22. doi: 10.1212/01.wnl.0000286942.14552.51. Epub 2008 Jan 9.

9.

[Search for the cause of Parkinson's disease].

Langston JW.

Arch Neurobiol (Madr). 1991 Nov-Dec;54(6):264-71. Review. Spanish. No abstract available.

PMID:
1811457
10.

Statins, cholesterol, Co-enzyme Q10, and Parkinson's disease.

Lieberman A, Lyons K, Levine J, Myerburg R.

Parkinsonism Relat Disord. 2005 Mar;11(2):81-4.

PMID:
15734664
11.
12.

Serum cholesterol, use of lipid-lowering drugs, and risk of Parkinson disease.

de Lau LM, Stricker BH, Breteler MM.

Mov Disord. 2007 Oct 15;22(13):1985. No abstract available.

PMID:
17557354
13.

Prospective study of caffeine consumption and risk of Parkinson's disease in men and women.

Ascherio A, Zhang SM, Hernán MA, Kawachi I, Colditz GA, Speizer FE, Willett WC.

Ann Neurol. 2001 Jul;50(1):56-63.

PMID:
11456310
14.

Therapeutic progress--review XX. Drug treatment of Parkinson's disease.

Pall HS, Williams AC, Ramsden DB.

J Clin Hosp Pharm. 1986 Aug;11(4):229-36. Review. No abstract available.

PMID:
3531240
15.

Parkinson's disease: current view.

Langston JW.

Am Fam Physician. 1987 Mar;35(3):201-6.

PMID:
3103408
16.

MAO-B and Parkinson's disease.

Sturman SG, Steventon GB, Waring RH, Williams AC.

Mov Disord. 1990;5(4):338-9. No abstract available.

PMID:
2259360
17.

Parkinson's disease worsened by nefazodone.

Benazzi F.

Int J Geriatr Psychiatry. 1997 Dec;12(12):1195. No abstract available.

PMID:
9444544
18.

Parkinson's disease.

Lieberman AN.

Compr Ther. 1986 Mar;12(3):25-9. No abstract available.

PMID:
3486090
19.

Parkinson's disease and cytochrome P450: a possible link?

Shahi GS, Das NP, Moochhala SM.

Med Hypotheses. 1990 Aug;32(4):277-82.

PMID:
2233418
20.

Environment, mitochondria, and Parkinson's disease.

Sherer TB, Betarbet R, Greenamyre JT.

Neuroscientist. 2002 Jun;8(3):192-7. Review.

PMID:
12061498
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk